Clinical deployment of antibodies for treatment of melanoma
• Melanoma treatment has been transformed using T-cell checkpoint antibodies. • Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management. • Combination T-cell checkpoint therapy holds great promise for clinical development. • OX40 and 4-1BB are T cell costimulators with clini...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Curti, Brendan D. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls - Gayda, Mathieu ELSEVIER, 2015, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:67 ; year:2015 ; number:2 ; pages:18-27 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.molimm.2015.01.025 |
|---|
| Katalog-ID: |
ELV023268697 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV023268697 | ||
| 003 | DE-627 | ||
| 005 | 20230623170013.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.molimm.2015.01.025 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015003000016.pica |
| 035 | |a (DE-627)ELV023268697 | ||
| 035 | |a (ELSEVIER)S0161-5890(15)00035-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |a 610 | |
| 082 | 0 | 4 | |a 570 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 630 |a 640 |a 610 |q VZ |
| 100 | 1 | |a Curti, Brendan D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical deployment of antibodies for treatment of melanoma |
| 264 | 1 | |c 2015 | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Melanoma treatment has been transformed using T-cell checkpoint antibodies. • Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management. • Combination T-cell checkpoint therapy holds great promise for clinical development. • OX40 and 4-1BB are T cell costimulators with clinical potential in melanoma. | ||
| 650 | 7 | |a OX40 |2 Elsevier | |
| 650 | 7 | |a Melanoma |2 Elsevier | |
| 650 | 7 | |a 4-1BB |2 Elsevier | |
| 650 | 7 | |a CTLA-4 |2 Elsevier | |
| 650 | 7 | |a PD-1 |2 Elsevier | |
| 700 | 1 | |a Urba, Walter J. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Gayda, Mathieu ELSEVIER |t Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls |d 2015 |g Amsterdam [u.a.] |w (DE-627)ELV012849286 |
| 773 | 1 | 8 | |g volume:67 |g year:2015 |g number:2 |g pages:18-27 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.molimm.2015.01.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_227 | ||
| 912 | |a GBV_ILN_674 | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2015 |e 2 |h 18-27 |g 10 | ||
| 953 | |2 045F |a 570 | ||
| author_variant |
b d c bd bdc |
|---|---|
| matchkey_str |
curtibrendandurbawalterj:2015----:lnclelyetfnioisotet |
| hierarchy_sort_str |
2015 |
| publishDate |
2015 |
| allfields |
10.1016/j.molimm.2015.01.025 doi GBVA2015003000016.pica (DE-627)ELV023268697 (ELSEVIER)S0161-5890(15)00035-8 DE-627 ger DE-627 rakwb eng 570 610 570 DE-600 610 DE-600 610 VZ 630 640 610 VZ Curti, Brendan D. verfasserin aut Clinical deployment of antibodies for treatment of melanoma 2015 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Melanoma treatment has been transformed using T-cell checkpoint antibodies. • Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management. • Combination T-cell checkpoint therapy holds great promise for clinical development. • OX40 and 4-1BB are T cell costimulators with clinical potential in melanoma. OX40 Elsevier Melanoma Elsevier 4-1BB Elsevier CTLA-4 Elsevier PD-1 Elsevier Urba, Walter J. oth Enthalten in Elsevier Gayda, Mathieu ELSEVIER Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls 2015 Amsterdam [u.a.] (DE-627)ELV012849286 volume:67 year:2015 number:2 pages:18-27 extent:10 https://doi.org/10.1016/j.molimm.2015.01.025 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_40 GBV_ILN_227 GBV_ILN_674 AR 67 2015 2 18-27 10 045F 570 |
| spelling |
10.1016/j.molimm.2015.01.025 doi GBVA2015003000016.pica (DE-627)ELV023268697 (ELSEVIER)S0161-5890(15)00035-8 DE-627 ger DE-627 rakwb eng 570 610 570 DE-600 610 DE-600 610 VZ 630 640 610 VZ Curti, Brendan D. verfasserin aut Clinical deployment of antibodies for treatment of melanoma 2015 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Melanoma treatment has been transformed using T-cell checkpoint antibodies. • Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management. • Combination T-cell checkpoint therapy holds great promise for clinical development. • OX40 and 4-1BB are T cell costimulators with clinical potential in melanoma. OX40 Elsevier Melanoma Elsevier 4-1BB Elsevier CTLA-4 Elsevier PD-1 Elsevier Urba, Walter J. oth Enthalten in Elsevier Gayda, Mathieu ELSEVIER Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls 2015 Amsterdam [u.a.] (DE-627)ELV012849286 volume:67 year:2015 number:2 pages:18-27 extent:10 https://doi.org/10.1016/j.molimm.2015.01.025 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_40 GBV_ILN_227 GBV_ILN_674 AR 67 2015 2 18-27 10 045F 570 |
| allfields_unstemmed |
10.1016/j.molimm.2015.01.025 doi GBVA2015003000016.pica (DE-627)ELV023268697 (ELSEVIER)S0161-5890(15)00035-8 DE-627 ger DE-627 rakwb eng 570 610 570 DE-600 610 DE-600 610 VZ 630 640 610 VZ Curti, Brendan D. verfasserin aut Clinical deployment of antibodies for treatment of melanoma 2015 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Melanoma treatment has been transformed using T-cell checkpoint antibodies. • Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management. • Combination T-cell checkpoint therapy holds great promise for clinical development. • OX40 and 4-1BB are T cell costimulators with clinical potential in melanoma. OX40 Elsevier Melanoma Elsevier 4-1BB Elsevier CTLA-4 Elsevier PD-1 Elsevier Urba, Walter J. oth Enthalten in Elsevier Gayda, Mathieu ELSEVIER Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls 2015 Amsterdam [u.a.] (DE-627)ELV012849286 volume:67 year:2015 number:2 pages:18-27 extent:10 https://doi.org/10.1016/j.molimm.2015.01.025 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_40 GBV_ILN_227 GBV_ILN_674 AR 67 2015 2 18-27 10 045F 570 |
| allfieldsGer |
10.1016/j.molimm.2015.01.025 doi GBVA2015003000016.pica (DE-627)ELV023268697 (ELSEVIER)S0161-5890(15)00035-8 DE-627 ger DE-627 rakwb eng 570 610 570 DE-600 610 DE-600 610 VZ 630 640 610 VZ Curti, Brendan D. verfasserin aut Clinical deployment of antibodies for treatment of melanoma 2015 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Melanoma treatment has been transformed using T-cell checkpoint antibodies. • Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management. • Combination T-cell checkpoint therapy holds great promise for clinical development. • OX40 and 4-1BB are T cell costimulators with clinical potential in melanoma. OX40 Elsevier Melanoma Elsevier 4-1BB Elsevier CTLA-4 Elsevier PD-1 Elsevier Urba, Walter J. oth Enthalten in Elsevier Gayda, Mathieu ELSEVIER Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls 2015 Amsterdam [u.a.] (DE-627)ELV012849286 volume:67 year:2015 number:2 pages:18-27 extent:10 https://doi.org/10.1016/j.molimm.2015.01.025 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_40 GBV_ILN_227 GBV_ILN_674 AR 67 2015 2 18-27 10 045F 570 |
| allfieldsSound |
10.1016/j.molimm.2015.01.025 doi GBVA2015003000016.pica (DE-627)ELV023268697 (ELSEVIER)S0161-5890(15)00035-8 DE-627 ger DE-627 rakwb eng 570 610 570 DE-600 610 DE-600 610 VZ 630 640 610 VZ Curti, Brendan D. verfasserin aut Clinical deployment of antibodies for treatment of melanoma 2015 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Melanoma treatment has been transformed using T-cell checkpoint antibodies. • Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management. • Combination T-cell checkpoint therapy holds great promise for clinical development. • OX40 and 4-1BB are T cell costimulators with clinical potential in melanoma. OX40 Elsevier Melanoma Elsevier 4-1BB Elsevier CTLA-4 Elsevier PD-1 Elsevier Urba, Walter J. oth Enthalten in Elsevier Gayda, Mathieu ELSEVIER Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls 2015 Amsterdam [u.a.] (DE-627)ELV012849286 volume:67 year:2015 number:2 pages:18-27 extent:10 https://doi.org/10.1016/j.molimm.2015.01.025 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_40 GBV_ILN_227 GBV_ILN_674 AR 67 2015 2 18-27 10 045F 570 |
| language |
English |
| source |
Enthalten in Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls Amsterdam [u.a.] volume:67 year:2015 number:2 pages:18-27 extent:10 |
| sourceStr |
Enthalten in Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls Amsterdam [u.a.] volume:67 year:2015 number:2 pages:18-27 extent:10 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
OX40 Melanoma 4-1BB CTLA-4 PD-1 |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls |
| authorswithroles_txt_mv |
Curti, Brendan D. @@aut@@ Urba, Walter J. @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV012849286 |
| dewey-sort |
3570 |
| id |
ELV023268697 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023268697</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623170013.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.molimm.2015.01.025</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015003000016.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023268697</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0161-5890(15)00035-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Curti, Brendan D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical deployment of antibodies for treatment of melanoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Melanoma treatment has been transformed using T-cell checkpoint antibodies. • Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management. • Combination T-cell checkpoint therapy holds great promise for clinical development. • OX40 and 4-1BB are T cell costimulators with clinical potential in melanoma.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">OX40</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Melanoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">4-1BB</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CTLA-4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD-1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Urba, Walter J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Gayda, Mathieu ELSEVIER</subfield><subfield code="t">Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls</subfield><subfield code="d">2015</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012849286</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:67</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:18-27</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.molimm.2015.01.025</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_227</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_674</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">67</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">18-27</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| author |
Curti, Brendan D. |
| spellingShingle |
Curti, Brendan D. ddc 570 ddc 610 ddc 630 Elsevier OX40 Elsevier Melanoma Elsevier 4-1BB Elsevier CTLA-4 Elsevier PD-1 Clinical deployment of antibodies for treatment of melanoma |
| authorStr |
Curti, Brendan D. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV012849286 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 610 - Medicine & health 630 - Agriculture & related technologies 640 - Home & family management |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 610 570 DE-600 610 DE-600 610 VZ 630 640 610 VZ Clinical deployment of antibodies for treatment of melanoma OX40 Elsevier Melanoma Elsevier 4-1BB Elsevier CTLA-4 Elsevier PD-1 Elsevier |
| topic |
ddc 570 ddc 610 ddc 630 Elsevier OX40 Elsevier Melanoma Elsevier 4-1BB Elsevier CTLA-4 Elsevier PD-1 |
| topic_unstemmed |
ddc 570 ddc 610 ddc 630 Elsevier OX40 Elsevier Melanoma Elsevier 4-1BB Elsevier CTLA-4 Elsevier PD-1 |
| topic_browse |
ddc 570 ddc 610 ddc 630 Elsevier OX40 Elsevier Melanoma Elsevier 4-1BB Elsevier CTLA-4 Elsevier PD-1 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
w j u wj wju |
| hierarchy_parent_title |
Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls |
| hierarchy_parent_id |
ELV012849286 |
| dewey-tens |
570 - Life sciences; biology 610 - Medicine & health 630 - Agriculture 640 - Home & family management |
| hierarchy_top_title |
Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV012849286 |
| title |
Clinical deployment of antibodies for treatment of melanoma |
| ctrlnum |
(DE-627)ELV023268697 (ELSEVIER)S0161-5890(15)00035-8 |
| title_full |
Clinical deployment of antibodies for treatment of melanoma |
| author_sort |
Curti, Brendan D. |
| journal |
Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls |
| journalStr |
Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
18 |
| author_browse |
Curti, Brendan D. |
| container_volume |
67 |
| physical |
10 |
| class |
570 610 570 DE-600 610 DE-600 610 VZ 630 640 610 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Curti, Brendan D. |
| doi_str_mv |
10.1016/j.molimm.2015.01.025 |
| dewey-full |
570 610 630 640 |
| title_sort |
clinical deployment of antibodies for treatment of melanoma |
| title_auth |
Clinical deployment of antibodies for treatment of melanoma |
| abstract |
• Melanoma treatment has been transformed using T-cell checkpoint antibodies. • Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management. • Combination T-cell checkpoint therapy holds great promise for clinical development. • OX40 and 4-1BB are T cell costimulators with clinical potential in melanoma. |
| abstractGer |
• Melanoma treatment has been transformed using T-cell checkpoint antibodies. • Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management. • Combination T-cell checkpoint therapy holds great promise for clinical development. • OX40 and 4-1BB are T cell costimulators with clinical potential in melanoma. |
| abstract_unstemmed |
• Melanoma treatment has been transformed using T-cell checkpoint antibodies. • Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management. • Combination T-cell checkpoint therapy holds great promise for clinical development. • OX40 and 4-1BB are T cell costimulators with clinical potential in melanoma. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_40 GBV_ILN_227 GBV_ILN_674 |
| container_issue |
2 |
| title_short |
Clinical deployment of antibodies for treatment of melanoma |
| url |
https://doi.org/10.1016/j.molimm.2015.01.025 |
| remote_bool |
true |
| author2 |
Urba, Walter J. |
| author2Str |
Urba, Walter J. |
| ppnlink |
ELV012849286 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.molimm.2015.01.025 |
| up_date |
2024-07-06T18:27:01.361Z |
| _version_ |
1803855248870080512 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023268697</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623170013.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.molimm.2015.01.025</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015003000016.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023268697</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0161-5890(15)00035-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Curti, Brendan D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical deployment of antibodies for treatment of melanoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Melanoma treatment has been transformed using T-cell checkpoint antibodies. • Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management. • Combination T-cell checkpoint therapy holds great promise for clinical development. • OX40 and 4-1BB are T cell costimulators with clinical potential in melanoma.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">OX40</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Melanoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">4-1BB</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CTLA-4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD-1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Urba, Walter J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Gayda, Mathieu ELSEVIER</subfield><subfield code="t">Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls</subfield><subfield code="d">2015</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012849286</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:67</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:18-27</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.molimm.2015.01.025</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_227</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_674</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">67</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">18-27</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| score |
7.400467 |